Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection

  • Nicola CoppolaEmail author
  • Federica Portunato
  • Antonio Riccardo Buonomo
  • Laura Staiano
  • Riccardo Scotto
  • Biagio Pinchera
  • Stefania De Pascalis
  • Daniela Caterina Amoruso
  • Salvatore Martini
  • Mariantonietta Pisaturo
  • Carmine Coppola
  • Ivan Gentile
Original Article


Background and aim

The impact of directly acting antiviral agent (DAA) regimens on renal function is not well defined and quite controversial. We evaluated the effect of DAAs on kidney function and the factors associated with an improvement or worsening.

Patients and methods

The changes in estimated glomerular filtration rate (eGFR) in a cohort of 403 patients treated with a DAA regimen were evaluated.


The overall sustained virological response (SVR12) rate was 98%. The median eGFR progressively increased throughout treatment from 84.54 ml/min/1.73 m2 (IQR 70.8–97.3) to 88.12 ml/min/1.73 m2. Conversely, rates of patients with a eGFR more than 60 ml/min/1.73 m2 progressively increased from 83.1% at baseline to 87.8% at 12 weeks post-treatment (p < 0.05). Considering the change in eGFR according to the different factors, a significant improvement in eGFR was observed in the patients without diabetes (p < 0.001), in those with cirrhosis (p < 0.05), in those receiving a Sof-based regimen (p < 0.01) or not receiving RBV (p < 0.05), in those with a baseline eGFR less than 60 ml/min/1.73 m2 (p < 0.001) and in those with SVR (p < 0.05). An improvement in eGFR (defined as an increase in baseline eGFR of at least 10 ml/min/1.73 m2) was observed in 148 patients (36.7%). At multivariate analysis, age (aHR 0.96; 95 CI 0.93–0.99, p < 0.01) and a diagnosis of diabetes (aHR 0.02; 95 CI 0.20–0.87, p < 0.05) were inversely and independently associated with improvement in renal function, while the presence of Child–Pugh B cirrhosis at baseline was associated with an improvement in renal function (aHR 3.07; 95 CI 1.49–6.30, p < 0.01).


DAAs correlate with an improvement in renal function, underlining the importance of hepatitis C virus eradication to achieve also an improvement in extra-hepatic disorders.


DAA Renal function CKD HCV infection eGFR 



Hepatitis C virus


Extra-hepatic manifestations


Chronic kidney disease (CKD)


End-stage renal disease


Sustained virological response


Directly acting antiviral agents


Estimated glomerular filtration rate


Hepatocellular carcinoma




Chronic Kidney Disease Epidemiology Collaboration


Kidney Disease Improving Global Outcome


1-Month of therapy


End of treatment


Week 12 after the end of treatment


Interquartile range


Hazard ratio

95 CI

95% confidence interval


Adjusted hazard ratio
















Author contributions

NC, IG and FP were responsible for the conception and design of the study and wrote the manuscript; ARB, CC and GB participated in the conception of the study and interpreted the data; LS, GP, SDP, SM, DCA and MP enrolled and followed up the patients; RS interpreted and analyzed the data and performed the statistical analysis. All the authors read and approved the manuscript.


This study was supported by a Grant from University of Campania (Grant no. 2017). NC received Grants from ViiV Healthcare, Janssen-Cilag, and Gilead Sciences; personal fees from Gilead Sciences, Abbvie, Bristol-Myers Squibb and Merck Sharp & Dohme IG was consultant for Abbvie, MSD and Cardiome. He received a Grant (in the framework of Fellowship program) from Gilead Sciences.

Compliance with ethical standards

Conflict of interest

All the authors of the manuscript declare that they have no conflict of interest in connection with this paper.

Ethical statement

The study was approved by Ethical Committee of University Federico II of Naples (no. 259/2018). All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all participants included in the study.

Supplementary material

40620_2019_608_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 15 kb)


  1. 1.
    Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61(1 Suppl):S45–S57CrossRefGoogle Scholar
  2. 2.
    Negro F, Forton D, Craxì A et al (2015) Extra-hepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149:1345–1360CrossRefGoogle Scholar
  3. 3.
    Gill K, Ghazinian H, Manch R et al (2016) Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int 10:415–423CrossRefGoogle Scholar
  4. 4.
    Latt N, Alachkar N, Gurakar A (2012) Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol 8:434–445Google Scholar
  5. 5.
    Gentile I, Coppola N, Buonomo AR et al (2014) Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs 23(9):1211–1223CrossRefGoogle Scholar
  6. 6.
    Gentile I, Maraolo AE, Buonomo AR et al (2015) The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov 10(12):1363–1377CrossRefGoogle Scholar
  7. 7.
    European Association for the Study of the Liver (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol. Google Scholar
  8. 8.
    Minutolo R, Aghemo A, Chirianni A et al (2018) Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). J Nephrol 31:685–712CrossRefGoogle Scholar
  9. 9.
    Aoufi-Rabih S, García-Agudo R, Londoño MC et al (2018) Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. J Nephrol 31:1–13CrossRefGoogle Scholar
  10. 10.
    Butt AA, Ren Y, Marks K et al (2017) Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES. Aliment Pharmacol Ther 45:150–159CrossRefGoogle Scholar
  11. 11.
    Aby ES, Dong TS, Kawamoto J et al (2017) Impact of sustained virologic response on chronic kidney disease progression in hepatitis C. World J Hepatol 9:1352–1360CrossRefGoogle Scholar
  12. 12.
    Mehta DA, Cohen E, Charafeddine M et al (2017) Effect of hepatitis C treatment with ombitasvir/paritaprevir/r + dasabuvir on renal, cardiovascular and metabolic extrahepatic manifestations: a post hoc analysis of phase 3 clinical trials. Infect Dis Ther 6:515–529CrossRefGoogle Scholar
  13. 13.
    Coppola N, Gentile I, Pasquale G et al (2013) Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 13:20–26Google Scholar
  14. 14.
    Coppola N, De Pascalis S, Messina V et al (2017) ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens. Antivir Ther 22:551–558CrossRefGoogle Scholar
  15. 15.
    Macera M, Stanzione M, Messina V et al (2017) Interferon-free regimens in hepatitis B surface antigen/anti-hepatitis C virus positive patients: the need to control hepatitis B virus replication to avoid hepatitis B virus reactivation. Clin Gastroenterol Hepatol 15:1800–1802CrossRefGoogle Scholar
  16. 16.
    Starace M, Minichini C, De Pascalis S et al (2018) Virological patterns of HCV patients with failure to interferon-free regimens. J Med Virol 90:942–950CrossRefGoogle Scholar
  17. 17.
    Procopet B, Berzigotti A (2017) Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep 5:79–89CrossRefGoogle Scholar
  18. 18.
    Gentile I, Viola C, Graf M et al (2009) A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 43:81–87CrossRefGoogle Scholar
  19. 19.
    Nyblom H, Bjornsson E, Simren M et al (2006) The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 26:840–845CrossRefGoogle Scholar
  20. 20.
    Gopal DV, Rosen HR (2000) Abnormal findings on liver function tests. Interpreting results to narrow the diagnosis and establish a prognosis. Postgrad Med 107:100–102CrossRefGoogle Scholar
  21. 21.
    Afdhal N, McHutchison J, Brown R et al (2008) Thrombocytopenia associated with chronic liver disease. J Hepatol 48:1000–1007CrossRefGoogle Scholar
  22. 22.
    Ramachandran J, Sajith KG, Priya S et al (2014) Serum cholinesterase is an excellent biomarker of liver cirrhosis. Trop Gastroenterol 35:15–20CrossRefGoogle Scholar
  23. 23.
    Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefGoogle Scholar
  24. 24.
    AASLD/IDSA HCV Guidance Pane (2015) l. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932–954CrossRefGoogle Scholar
  25. 25.
    Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612CrossRefGoogle Scholar
  26. 26.
    Stevens PE, Levin A (2013) Kidney disease: improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830CrossRefGoogle Scholar
  27. 27.
    American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62–S69CrossRefGoogle Scholar
  28. 28.
    Sise ME, Backman E, Ortiz GA, Hundemer GL et al (2017) Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD. Clin J Am Soc Nephrol 12:1615–1623CrossRefGoogle Scholar
  29. 29.
    Alvarez-Ossorio MJ, Sarmento E, Castro R et al (2018) Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. J Viral Hepat 25:699–706CrossRefGoogle Scholar
  30. 30.
    Mallet V, Parlati L, Dorval O et al (2018) Estimated glomerular filtration rate variations and direct acting antivirals treatment for chronic hepatitis C: a retrospective longitudinal study. J Hepatol 68:S1–S36CrossRefGoogle Scholar
  31. 31.
    Taramasso L, Di Biagio A, Bovis F et al (2018) Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One 13:e0192627CrossRefGoogle Scholar

Copyright information

© Italian Society of Nephrology 2019

Authors and Affiliations

  • Nicola Coppola
    • 1
    • 5
    Email author
  • Federica Portunato
    • 1
  • Antonio Riccardo Buonomo
    • 2
  • Laura Staiano
    • 3
  • Riccardo Scotto
    • 2
  • Biagio Pinchera
    • 2
  • Stefania De Pascalis
    • 1
  • Daniela Caterina Amoruso
    • 3
  • Salvatore Martini
    • 4
  • Mariantonietta Pisaturo
    • 1
  • Carmine Coppola
    • 3
  • Ivan Gentile
    • 2
  1. 1.Infectious Diseases Unit, Department of Mental Health and Public MedicineUniversity of Campania Luigi VanvitelliCasertaItaly
  2. 2.Section of Infectious Diseases, Department of Clinical Medicine and SurgeryUniversity of Naples Federico IINaplesItaly
  3. 3.Unit of Hepatology and Interventional Ultrasonography, Department of Internal MedicineOORR Area Stabiese, Plesso Nuovo GragnanoNaplesItaly
  4. 4.HIV UnitUniversity of CampaniaNaplesItaly
  5. 5.Department of Mental and Public Health, Section of Infectious DiseasesUniversity of CamapaniaNaplesItaly

Personalised recommendations